{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:45:33Z","timestamp":1793339133737,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jacadv.2023.100557","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T18:16:25Z","timestamp":1692728185000},"page":"100557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke\u00a0Survivors"],"prefix":"10.1016","volume":"2","author":[{"given":"K\u00e9vin","family":"Chemello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis F.","family":"Guedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Techer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Croyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Swietek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Meilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-0685","authenticated-orcid":false,"given":"Gilles","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacadv.2023.100557_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.jacadv.2023.100557_bib3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacadv.2023.100557_bib4","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2023.100557_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacadv.2023.100557_bib7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.1995.03520400039041","article-title":"Plasma concentration of lipoprotein(a) and the risk of future stroke","volume":"273","author":"Ridker","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100557_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000319067","article-title":"Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME study","volume":"30","author":"Canou\u00ef-Poitrine","year":"2010","journal-title":"Cerebrovasc Dis"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100557_bib9","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein (a) and risk of coronary, cerebrovascular and peripheral artery disease; the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and incident ischemic stroke","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100557_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lipoprotein(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacadv.2023.100557_bib16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jacc.2020.03.015","article-title":"Atorvastatin reduces first and subsequent vascular events across vascular territories: the SPARCL trial","volume":"75","author":"Szarek","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100557_bib17","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1161\/STROKEAHA.108.516450","article-title":"Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis","volume":"39","author":"Sillesen","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100557_bib18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/STROKEAHA.109.564781","article-title":"Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease","volume":"41","author":"Amarenco","year":"2010","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00273171.2011.540480","article-title":"A\u00a0tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/joim.12197","article-title":"JIM-13-0560 R1: propensity scores for confounder adjustment when assessing the effects of medical interventions using non-experimental study designs","volume":"275","author":"St\u00fcrmer","year":"2014","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"10.1016\/j.jacadv.2023.100557_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the sub distribution of a competing risk","volume":"99","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"8","key":"10.1016\/j.jacadv.2023.100557_bib23","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/STROKEAHA.121.034924","article-title":"Effect of lipoprotein(a) on stroke recurrence attenuates at low LDL-C (low-density lipoprotein) and inflammation levels","volume":"53","author":"Xu","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/CIRCGENETICS.110.958371","article-title":"Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the heart protection study","volume":"4","author":"Hopewell","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.jacadv.2023.100557_bib26","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1161\/01.STR.0000239694.19359.88","article-title":"Risk factors for ischemic stroke subtypes","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100557_bib27","article-title":"Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (atherosclerosis risk in communities) study","volume":"6","author":"Aronis","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100557_bib28","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [Lipoprotein(a)] level on ischemic stroke and Alzheimer disease","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"issue":"22","key":"10.1016\/j.jacadv.2023.100557_bib29","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2023.100557_bib30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.120.046774","article-title":"Carotid atherosclerosis evolution when targeting a low-density lipoprotein cholesterol concentration <70\u00a0mg\/dL after an ischemic stroke of atherosclerotic origin","volume":"142","author":"Amarenco","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A\u00a0comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100557_bib32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacadv.2023.100557_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"44","key":"10.1016\/j.jacadv.2023.100557_bib34","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100557_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacadv.2023.100557_bib36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacadv.2023.100557_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacc.2016.10.057","article-title":"Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack","volume":"69","author":"Byun","year":"2017","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.jacadv.2023.100557_bib38","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A\u00a0novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J\u00a0Lipid Res"},{"issue":"10","key":"10.1016\/j.jacadv.2023.100557_bib39","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)1","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"issue":"8","key":"10.1016\/j.jacadv.2023.100557_bib40","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.jacadv.2023.100557_bib42","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100557_bib43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacadv.2023.100557_bib44","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100557_bib45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"M\u00fcller","year":"2015","journal-title":"J\u00a0Lipid Res"},{"issue":"10289","key":"10.1016\/j.jacadv.2023.100557_bib46","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2023.100557_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100557_bib48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100557_bib49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jacadv.2023.100557_bib50","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X23004878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X23004878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:56:35Z","timestamp":1757426195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X23004878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2772963X23004878"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2023.100557","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke\u00a0Survivors","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2023.100557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100557"}}